<DOC>
	<DOCNO>NCT00912899</DOCNO>
	<brief_summary>This phase 1 study evaluate safety determine maximum tolerate dose , safety &amp; tolerability noscapine HCl patient advance multiple myeloma</brief_summary>
	<brief_title>A Study Noscapine HCl ( CB3304 ) Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Noscapine</mesh_term>
	<criteria>Advanced Multiple Myeloma . Progression ≥ 2 line prior therapy , include least one steroid , one immunomodulatory agent ( iMID ) , one alkylator , bortezomib ( VELCADE® ) . ECOG performance status either 0 1 . Prior chemotherapy antimicrotubule agent Metastasis involve brain spinal cord Clinically significant lung heart disease Abnormal electrocardiogram Please note additional inclusion exclusion criterion . The study center determine meet criterion . Site personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , site personnel explain reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Refractory Multiple Myeloma</keyword>
	<keyword>CB3304</keyword>
	<keyword>Noscapine HCl</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>